Next Article in Journal
Biomarkers and Imaging Findings of Anderson–Fabry Disease—What We Know Now
Previous Article in Journal
The Role of the MAPK Signaling, Topoisomerase and Dietary Bioactives in Controlling Cancer Incidence
Article Menu

Export Article

Open AccessFeature PaperReview
Diseases 2017, 5(2), 14; doi:10.3390/diseases5020014

Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure

School of Medicine, Flinders University, Adelaide 5042, Australia
Division of Molecular and Clinical Medicine, Mailbox 2, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
Author to whom correspondence should be addressed.
Academic Editor: Maurizio Battino
Received: 25 February 2017 / Revised: 21 April 2017 / Accepted: 27 April 2017 / Published: 10 May 2017
(This article belongs to the Special Issue Current and Potential Therapeutic Strategies for Heart Failure)
View Full-Text   |   Download PDF [498 KB, uploaded 12 May 2017]   |  


Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high. An alternative approach is currently being developed, which targets myocardial energy efficiency and the dysfunction of the cardiac mitochondria. Emerging evidence suggests that the insufficient availability of ATP to the failing myocardium can be attributed to abnormalities in the myocardial utilisation of its substrates rather than an overall lack of substrate availability. Therefore, the development of potential metabolic therapeutics has commenced including trimetazidine, ranolazine and perhexiline, as well as specific mitochondrial-targeting pharmaceuticals, such as elamipretide. Large randomised controlled trials are required to confirm the role of metabolic-modulating drugs in the treatment of heart failure, but early studies have been promising in their possible efficacy for the management of heart failure in the future. View Full-Text
Keywords: heart failure; metabolic; mitochondria; trimetazidine; ranolazine; perhexiline; elamipretide heart failure; metabolic; mitochondria; trimetazidine; ranolazine; perhexiline; elamipretide

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Steggall, A.; Mordi, I.R.; Lang, C.C. Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. Diseases 2017, 5, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top